Market Price

38.27 

-0.18 -0.5%

as of Aug 06 '20

52 Week Range:

27.88 40.97


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, such as cardiovascular metabolic and pain under the Eliquis, Chantix/Champix, and Premarin family brands; oncology, such as biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Sutent, Xtandi, Xalkori, Inlyta, Braftovi + Mektovi brands; and sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Vfend, and Zithromax brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, and tick-borne encephalitis under the Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix, and Trumenba brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, and Eucrisa brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, Genotropin, and Refacto AF/Xyntha brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration and/or co-promotion agreements with Bristol-Myers Squibb Company and Astellas Pharma US, Inc.; licensing agreement with Akcea Therapeutics, Inc; strategic alliance with Verily Life Sciences LLC; collaboration agreements with Merck KGaA and Valneva SE; clinical trial collaboration and supply agreement with IDEAYA Biosciences, Inc.; material transfer and collaboration agreement with BioNTech SE to co-develop COVID-19 vaccine; clinical supply collaboration with Jiangsu Alphamab Biopharmaceuticals Co., Ltd; and research collaboration and license agreement with BioInvent International AB. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Oct '16 Oct '17 Dec '18 Dec '19
Equity (BVPS) 11.15
10.95
11.88
11.16
12.18
12.39
10.82
10.43
10.16
12.47
11.76
growth rate -1.8% 8.5% -6.1% 9.1% 1.7% -12.7% -3.6% -2.6% 22.7% -5.7%
Earnings BIT 10,830.00
9,420.00
12,760.00
12,080.00
15,720.00
15,663.00
13,791.00
14,098.00
14,711.00
15,724.00
15,042.00
growth rate -13.0% 35.5% -5.3% 30.1% -0.4% -12.0% 2.2% 4.4% 6.9% -4.3%
Avg.PE 14.79
17.15
19.49
19.92
18.55
23.89
26.72
29.21
10.55
23.03
13.08
growth rate 16.0% 13.6% 2.2% -6.9% 28.8% 11.9% 9.3% -63.9% 118.3% -43.2%
ROA 5.33
4.05
5.23
7.79
12.29
5.35
4.13
4.26
12.41
6.73
9.96
growth rate -24.0% 29.1% 49.0% 57.8% -56.5% -22.8% 3.2% 191.3% -45.8% 48.0%
ROE 11.71
9.29
11.78
17.83
27.94
12.38
10.24
11.62
32.58
16.56
25.72
growth rate -20.7% 26.8% 51.4% 56.7% -55.7% -17.3% 13.5% 180.4% -49.2% 55.3%
ROIC 8.46
7.02
8.58
12.90
19.65
8.91
7.11
7.63
20.18
10.98
15.89
growth rate -17.0% 22.2% 50.4% 52.3% -54.7% -20.2% 7.3% 164.5% -45.6% 44.7%
Cur. Ratio 1.66
2.11
2.06
2.14
2.41
2.67
1.49
1.25
1.35
1.57
0.88
growth rate 27.1% -2.4% 3.9% 12.6% 10.8% -44.2% -16.1% 8.0% 16.3% -44.0%
Quick Ratio 1.12
1.51
1.78
1.90
1.79
2.07
1.16
0.94
1.03
0.94
0.58
growth rate 34.8% 17.9% 6.7% -5.8% 15.6% -44.0% -19.0% 9.6% -8.7% -38.3%
Leverage 2.37
2.22
2.29
2.29
2.26
2.38
2.59
2.88
2.41
2.52
2.65
growth rate -6.3% 3.2% 0.0% -1.3% 5.3% 8.8% 11.2% -16.3% 4.6% 5.2%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Oct '16 Oct '17 Dec '18 Dec '19
Acct.Receivable 14,645.00
14,612.00
22,438.00
16,845.00
13,981.00
10,967.00
10,838.00
11,266.00
11,271.00
11,399.00
12,068.00
growth rate -0.2% 53.6% -24.9% -17.0% -21.6% -1.2% 4.0% 0.0% 1.1% 5.9%
Acct.Payable 8,603.00
7,508.00
7,367.00
3,210.00
3,620.00
4,536.00
4,656.00
4,674.00
4,220.00
growth rate -12.7% -1.9% -56.4% 12.8% 25.3% 2.7% 0.4% -9.7%
Cur.Assets 61,670.00
60,468.00
60,817.00
64,831.00
56,244.00
55,595.00
43,804.00
38,949.00
41,142.00
49,926.00
32,803.00
growth rate -2.0% 0.6% 6.6% -13.3% -1.2% -21.2% -11.1% 5.6% 21.4% -34.3%
Total Assets 212,949.00
195,014.00
188,002.00
185,798.00
172,101.00
167,566.00
167,381.00
171,615.00
171,797.00
159,422.00
167,489.00
growth rate -8.4% -3.6% -1.2% -7.4% -2.6% -0.1% 2.5% 0.1% -7.2% 5.1%
Cash 1,978.00
1,735.00
3,182.00
10,081.00
2,183.00
3,343.00
3,641.00
2,595.00
1,342.00
1,139.00
1,305.00
growth rate -12.3% 83.4% 216.8% -78.4% 53.1% 8.9% -28.7% -48.3% -15.1% 14.6%
Inventory 12,403.00
8,405.00
6,610.00
6,076.00
6,166.00
5,663.00
7,513.00
6,783.00
7,578.00
7,508.00
8,283.00
growth rate -32.2% -21.4% -8.1% 1.5% -8.2% 32.7% -9.7% 11.7% -0.9% 10.3%
Cur.Liabilities 37,225.00
28,609.00
28,909.00
29,186.00
23,366.00
21,587.00
29,398.00
31,115.00
30,427.00
31,858.00
37,304.00
growth rate -23.2% 1.1% 1.0% -19.9% -7.6% 36.2% 5.8% -2.2% 4.7% 17.1%
Liabilities 122,935.00
107,201.00
105,812.00
104,538.00
95,794.00
95,944.00
102,383.00
111,775.00
100,141.00
95,664.00
104,043.00
growth rate -12.8% -1.3% -1.2% -8.4% 0.2% 6.7% 9.2% -10.4% -4.5% 8.8%
LT Debt 43,193.00
38,410.00
41,812.00
37,617.00
34,455.00
31,557.00
28,874.00
31,545.00
33,715.00
33,287.00
35,955.00
growth rate -11.1% 8.9% -10.0% -8.4% -8.4% -8.5% 9.3% 6.9% -1.3% 8.0%
Equity 90,014.00
87,813.00
82,190.00
81,260.00
76,307.00
71,272.00
64,694.00
59,520.00
71,287.00
63,388.00
63,126.00
growth rate -2.5% -6.4% -1.1% -6.1% -6.6% -9.2% -8.0% 19.8% -11.1% -0.4%
Common Shares 7,045.00
8,074.00
7,870.00
7,508.00
6,895.00
6,424.00
6,257.00
6,159.00
6,058.00
5,977.00
5,675.00
growth rate 14.6% -2.5% -4.6% -8.2% -6.8% -2.6% -1.6% -1.6% -1.3% -5.1%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Oct '16 Oct '17 Dec '18 Dec '19
Capital Expenditures 1,205.00
1,513.00
1,660.00
1,327.00
1,206.00
1,199.00
1,397.00
1,823.00
1,956.00
2,042.00
2,176.00
growth rate 25.6% 9.7% -20.1% -9.1% -0.6% 16.5% 30.5% 7.3% 4.4% 6.6%
Cash Dividends 5,548.00
6,088.00
6,234.00
6,534.00
6,580.00
6,609.00
6,940.00
7,317.00
7,659.00
7,978.00
8,043.00
growth rate 9.7% 2.4% 4.8% 0.7% 0.4% 5.0% 5.4% 4.7% 4.2% 0.8%
Cash From OA 16,587.00
11,454.00
20,240.00
16,746.00
17,684.00
17,084.00
14,688.00
16,192.00
16,802.00
15,827.00
12,588.00
growth rate -31.0% 76.7% -17.3% 5.6% -3.4% -14.0% 10.2% 3.8% -5.8% -20.5%
FCF per Share 2.18
1.23
2.47
2.09
2.24
2.41
2.22
2.06
2.19
2.61
1.90
growth rate -43.6% 100.8% -15.4% 7.2% 7.6% -7.9% -7.2% 6.3% 19.2% -27.2%
Sale Purchase of Stock -8,847.00
-7,660.00
-14,540.00
1,002.00
1,263.00
1,019.00
862.00
growth rate 0.0% 0.0% 100.0% 26.1% -19.3% -15.4%
FCF 15,382.00
9,941.00
18,580.00
15,727.00
16,300.00
15,300.00
13,016.00
13,902.00
14,253.00
13,631.00
9,994.00
growth rate -35.4% 86.9% -15.4% 3.6% -6.1% -14.9% 6.8% 2.5% -4.4% -26.7%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Oct '16 Oct '17 Dec '18 Dec '19
Sales 50,009.00
65,165.00
61,035.00
54,657.00
51,584.00
49,605.00
48,851.00
52,824.00
52,546.00
53,647.00
51,750.00
growth rate 30.3% -6.3% -10.5% -5.6% -3.8% -1.5% 8.1% -0.5% 2.1% -3.5%
Op.Income 10,827.00
9,471.00
7,860.00
9,021.00
11,410.00
15,663.00
13,791.00
14,098.00
14,711.00
15,724.00
15,042.00
growth rate -12.5% -17.0% 14.8% 26.5% 37.3% -12.0% 2.2% 4.4% 6.9% -4.3%
IBT 10,827.00
9,471.00
11,481.00
11,242.00
15,716.00
12,238.00
8,965.00
8,353.00
12,304.00
11,885.00
17,682.00
growth rate -12.5% 21.2% -2.1% 39.8% -22.1% -26.7% -6.8% 47.3% -3.4% 48.8%
Net Income 8,635.00
8,257.00
7,860.00
9,021.00
11,410.00
9,135.00
6,960.00
7,215.00
21,308.00
11,153.00
16,273.00
growth rate -4.4% -4.8% 14.8% 26.5% -19.9% -23.8% 3.7% 195.3% -47.7% 45.9%
EPS 1.23
1.02
1.27
1.94
3.19
1.42
1.11
1.17
3.52
1.87
2.87
growth rate -17.1% 24.5% 52.8% 64.4% -55.5% -21.8% 5.4% 200.9% -46.9% 53.5%
Gross Profit 41,121.00
50,377.00
48,535.00
44,836.00
41,998.00
40,572.00
39,490.00
40,906.00
41,720.00
42,519.00
41,739.00
growth rate 22.5% -3.7% -7.6% -6.3% -3.4% -2.7% 3.6% 2.0% 1.9% -1.8%
R&D 7,845.00
9,483.00
8,681.00
7,482.00
6,678.00
7,150.00
7,646.00
7,858.00
7,645.00
7,959.00
7,984.00
growth rate 20.9% -8.5% -13.8% -10.8% 7.1% 6.9% 2.8% -2.7% 4.1% 0.3%

Quarterly Statements

Item Name Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Earnings BIT 4,561.00
4,298.00
3,896.00
2,287.00
4,391.00
growth rate -5.8% -9.4% -41.3% 92.0%
Balance Sheet Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Acct.Receivable 13,197.00
13,516.00
13,169.00
12,068.00
13,227.00
growth rate 2.4% -2.6% -8.4% 9.6%
Acct.Payable 4,156.00
4,002.00
3,942.00
4,220.00
3,972.00
growth rate -3.7% -1.5% 7.1% -5.9%
Cur.Assets 45,290.00
47,073.00
33,459.00
32,803.00
34,737.00
growth rate 3.9% -28.9% -2.0% 5.9%
Total Assets 155,421.00
156,199.00
170,446.00
167,489.00
166,336.00
growth rate 0.5% 9.1% -1.7% -0.7%
Cash 1,937.00
1,784.00
2,785.00
1,305.00
2,151.00
growth rate -7.9% 56.1% -53.1% 64.8%
Inventory 8,029.00
8,233.00
8,222.00
8,283.00
8,423.00
growth rate 2.5% -0.1% 0.7% 1.7%
Cur.Liabilities 29,423.00
32,030.00
36,974.00
37,304.00
33,890.00
growth rate 8.9% 15.4% 0.9% -9.2%
Liabilities 96,263.00
96,274.00
105,051.00
104,043.00
100,998.00
growth rate 0.0% 9.1% -1.0% -2.9%
LT Debt 35,911.00
36,168.00
36,044.00
35,955.00
36,281.00
growth rate 0.7% -0.3% -0.3% 0.9%
Equity 58,787.00
59,550.00
65,084.00
63,126.00
65,009.00
growth rate 1.3% 9.3% -3.0% 3.0%
Common Shares 468.00
468.00
468.00
468.00
470.00
growth rate 0.0% 0.0% 0.0% 0.4%
Cash Flow Statement Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Capital Expenditures 460.00
479.00
565.00
672.00
463.00
growth rate 4.1% 18.0% 18.9% -31.1%
Cash Dividends 2,045.00
2,002.00
2,004.00
1,992.00
2,105.00
growth rate -2.1% 0.1% -0.6% 5.7%
Cash From OA 1,698.00
2,611.00
4,510.00
3,769.00
3,133.00
growth rate 53.8% 72.7% -16.4% -16.9%
Sale Purchase of Stock
growth rate
FCF 1,238.00
2,132.00
3,945.00
3,097.00
2,670.00
growth rate 72.2% 85.0% -21.5% -13.8%
Income Statement Mar '19 Jun '19 Sep '19 Dec '19 Mar '20
Sales 13,118.00
13,264.00
12,680.00
12,688.00
12,028.00
growth rate 1.1% -4.4% 0.1% -5.2%
Op.Income 4,561.00
4,298.00
3,896.00
2,287.00
4,391.00
growth rate -5.8% -9.4% -41.3% 92.0%
IBT 4,323.00
4,141.00
10,727.00
-1,508.00
3,885.00
growth rate -4.2% 159.0% -100.0% 100.0%
Net Income 3,884.00
5,046.00
7,680.00
-336.00
3,401.00
growth rate 29.9% 52.2% -100.0% 100.0%
EPS
growth rate
Gross Profit 10,707.00
10,714.00
10,225.00
10,092.00
9,682.00
growth rate 0.1% -4.6% -1.3% -4.1%
R&D 1,692.00
1,824.00
1,940.00
2,529.00
1,729.00
growth rate 7.8% 6.4% 30.4% -31.6%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

F (2.43)

YOY Growth Grade:

F (4.10)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 15.18 15.15 11.48
EPS / Growth 8.7% 2.53 5.4%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 1.0%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 1.0% 5.0% 5.0%
Future PE 2.00 12.23 12.23
Future EPS 2.79 4.12 4.12
Value Price
MOS %
1.38
-96.4%
12.45
-67.5%
12.45
-67.5%
MOS Price 0.69 6.22 6.22
IRT 14.05 11.12 11.12

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.